Gender differences in treatment of Coronavirus Disease-2019

https://doi.org/10.4081/monaldi.2020.1508

Authors

  • Immacolata Ambrosino | imma-ambrosino@libero.it Local Healthcare Unit of Bari, Health District 10, Italy. https://orcid.org/0000-0003-3817-1828
  • Elena Barbagelata Department of Internal Medicine, Lavagna Hospital, Genoa, Italy. https://orcid.org/0000-0001-7357-4388
  • Graziamaria Corbi Department of Medicine and Health Sciences, University of Molise; Gender Medicine and Aging (GEMEA) Group of the Italian Society of Gerontology and Geriatrics (SIGG), Italy. https://orcid.org/0000-0002-3441-889X
  • Tiziana Ciarambino Department of Internal Medicine, Marcianise Hospital, ASL Caserta, Italy.
  • Cecilia Politi Head of Gender Medicine Area F.A.D.O.I. (Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti), Isernia, Italy.
  • Anna Maria Moretti President of GISeG, Italian Group for Health and Gender, Bari, Italy.

Abstract

Coronavirus Disease-2019 (COVID-19) is the worst worldwide pandemic with more than 12,000,000 cases and 560,000 deaths until 14th July 2020. Men were more infected by COVID-19 than women, and male subjects with underlying conditions, including diabetes, hypertension, and cardiovascular diseases developed a severe form of the affection, with increased mortality rate. Many factors can contribute to the disparity in disease outcomes, such as hormone-specific reaction and activity of X-linked genes, which modulate the innate and adaptive immune response to virus infection. Until now, only the Remdesivir was approved by FDA (Food Drug Administration) for COVID-19 treatment, although several clinical trials are ongoing worldwide also on other drugs. In this review, we analyzed published studies on several drugs (chloroquine or hydroxychloroquine, remdesivir, favipiravir, lopinavir-ritonavir in combination, tocilizumab, plasma, and immunoglobulins) with some efficacy to COVID-19 in humans, and evaluated if there were a gender analysis of the available data. In our opinion, it is essential to report data about COVID-19 disaggregated by sex, age, and race, because the knowledge of gender differences is fundamental to identify effective and customized treatments to reduce hospitalizations, admissions to intensive care units, and mortality.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2020-12-03
Info
Issue
Section
COVID-19 - Collection of articles on the Coronavirus outbreak
Keywords:
Gender, differences, treatment, COVID-19
Statistics
  • Abstract views: 768

  • PDF: 522
How to Cite
Ambrosino, Immacolata, Elena Barbagelata, Graziamaria Corbi, Tiziana Ciarambino, Cecilia Politi, and Anna Maria Moretti. 2020. “Gender Differences in Treatment of Coronavirus Disease-2019”. Monaldi Archives for Chest Disease 90 (4). https://doi.org/10.4081/monaldi.2020.1508.

Most read articles by the same author(s)